



AlzChem Group AG

Andreas Niedermaier, CEO
Dr. Georg Weichselbaumer, CSO

August 11, 2020



DISCLAIMER



Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the AlzChem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, AlzChem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst Presentation Q2/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS


Summary of business development Q2/2020 Financial Report

Best performance within last 10 quarters

Dividend paid as per plan

1. virtual Annual General Meeting

Lower commodity prices support earnings



Excellent performance in Creamino® in line with growth plan

COVID-19: stable production without interruptions

COVID-19: negligible impact on supply chains

Bioselect® products key contributor in Q2

APPLICATION

MARKET

USED IN



DIAGNOSTICS



Diagnostic test kits for detection of DNA and RNA





PHARMA / API



Biopharmaceutical production process for manufacturing drugs (e.g. autoimmune diseases and cancer)

→ Only European source with complete backward integration





FINANCIAL OVERVIEW Q2/2020



Key figures within guidance

AlzChem Group	Q2 2019	Q2 2020	yoy %	2019 1 - 6	2020 1 - 6	yoy %
SALES (in M€)	96.1	102.5	+6.6%	188.2	197.3	+4.8%
EBITDA (in M€)	14.6	16.8	+15.0%	27.9	29.1	+4.6%
EBITDA margin (in %)	15.2%	16.4%	+1.2 pp	14.8%	14.8%	-0.0pp
Earnings per Share (in €)	0.62	0.66	+5.8%	1.16	1.09	-6.4%

COMMENTS


- Strong sales in Q2, first half-2020 closed with significant growth
- Revitalized multi-purpose plant business, significant growth in the pharmaceuticals sector
- Favorable raw materials environment supports growth in EBITDA
- Higher depreciation leads to lower earnings per share

SALES ANALYSIS	DELTA Q2	DELTA JUN YTD
Volume	+5.0%	+3.6%
Price	+1.0%	+0.7%
Currency	+0.6%	+0.5%


BEST PERFORMANCE WITHIN LAST 10 QUARTERS

Business drivers support stronger Q2

SALES



EBITDA



AGENDA

Analyst Presentation Q2/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BASICS & INTERMEDIATES SEGMENT

Our integrated system



DESCRIPTION

The "Basics & Intermediates" segment comprises the production of **basic and intermediate products** that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

SELECTED PRODUCTS




NITRALZ®




BASICS & INTERMEDIATES SEGMENT

Steel and automotive weakness offset by pharma and agro


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+0.3%	0.0%
Price	+0.5%	+1.0%
Currency	+0.4%	+0.4%

COMMENTS

- Q2/2020 sales slightly higher than previous year
- Continued strong Nitriles performance based on new production capacities installed in 2019
- Strong Perlka® volumes
- Improved DCD volumes compared to previous year based on increased Agro and Pharma demand
- Business environment in metallurgic business deteriorated compared to Q1/2020, outlook remains challenging
- Encouraging EBITDA margin of ~5.9% (previous year 1.7%)

SPECIALTY CHEMICALS SEGMENT

Our growth focus



DESCRIPTION

The "Specialty Chemicals" segment produces and sells **high-quality growth products** in the area of specialty chemicals.

SELECTED PRODUCTS

 **Creapure**®

DYHARD®

 **Dormex**®

**LIVA
DUR**®

CREAMINO


Bioselect®



SPECIALTY CHEMICALS SEGMENT

Further on the forecasted growth path – despite COVID-19

SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+9.9%	+7.2%
Price	+1.3%	+0.2%
Currency	+0.8%	+0.7%

COMMENTS

- Q2/2020 sales ~ 12% above previous year level
- Stable increasing Creamino® volumes
- High demand for pharma raw materials (Multipurpose Plants and Bioselect®)
- Creapure® volumes below last year
- DYHARD® under pressure due to lower demand from automotive sector as well as renewable energy (temporary shutdown in USA)
- Results burdened with startup costs for LIVADUR® and Your Encour!™
- EBITDA margin of ~22.4%

OTHER & HOLDING SEGMENT

Further activities



DESCRIPTION

The "Other & Holding" segment offers **infrastructure** and **energy supply** services at our locations for the chemicals segments and for external customers.


The segment also comprises all activities that cannot be allocated to the other segments.




OTHER & HOLDING SEGMENT

Service sales almost stable with a slight downward trend

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	-5.5%	-4.5%
Price	+2.5%	+2.4%
Currency	0.0%	0.0%

COMMENTS


- Overall sales on previous year's level
- Slightly less demand in maintenance and energy supply
- Decreasing consumable costs can cover other cost increases e.g. labor costs
- Earnings affected by slightly higher maintenance costs to modernize infrastructure

BALANCE SHEET

AlzChem Group AG (M€)




ASSETS



- Lower other non-current assets due to major capex projects in 2019 (capex below depreciation)
- Positive impact from inventory optimization project
- Usual increase in receivables as of record date; no notable overdue receivables


LIABILITIES



- Higher short-term loans at record date (dividend payout and temporarily higher trade receivables)
- Lower other non-current liabilities because of regular repayment of long-term loans

CASHFLOW

Positive free cashflow due to strong cash inflow from ongoing operations



COMMENTS

- Strong cash inflow from ongoing operations
- Positive effect of inventory reduction on cashflow from ongoing operations
- Investing cashflow below prior year's level due to main CAPEX projects Creamino® and NITRALZ® in 2019
- Cashflow from financing activities (-1.0 M€) – main effects: scheduled repayment of long-term bank loans (-6.0 M€), deposits of short-term financing lines (+13.7 M€), dividend payments (-7.6 M€) as well as repayment of lease liabilities (-0.9 M€)
- Previous year's cashflow from financing activities: payout of the loan (30.1 M€)

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers

IMPLEMENTATION OF THE CREAMINO® GROWTH


ON THE WAY

- Increase number of trials worldwide
- Reinforce technical staff – to train distributors more intensively
- Turning trials into sales
- Initiate further studies (pig and chicken)

REALIZATION OF THE NEXT CAPACITY EXPANSIONS

- Acquisition of customer contracts
- Preparation of the final CAPEX planning
- Supervisory Board approval
- Start of construction of the plant

SHORTLY BEFORE REALIZATION



ESTABLISH FIRST SALES OF LIVADUR®

TEST PHASE RUNNING

- Training pharmacists
- Push various promotion activities (radio spots, podcasts...)
- Now available at online pharmacies
- Analysis ASIA market entry
- First test sales in USA, branded by Your Encour!™

SUSTAINABILITY

- Define and set the tone with CO₂ neutral growth
- Zero accidents and incidents

PROJECT LAUNCHED


MANAGEMENT OF COVID-19 EFFECTS

CONSTANTLY CHALLENGES US


OUTLOOK 2020

Outlook confirmed, but expected on the lower end of the guidance

SALES



EBITDA



COMMENTS

- Start of the expected Creamino® ramp-up in second half of the year after completion of ongoing feeding trials
- Reinforcement of custom manufacturing
- Continued low demand for steel at least for Q3
- Further stable growth of NITRALZ® business
- Significant business expansion in the pharmaceutical industry
- Signs of delayed recovery of the global economic environment in H2 / 2020 (U-shaped)
- results expected on the lower end of the guidance

FINANCIAL CALENDAR

Upcoming dates



2020	SEP 21	Baader Investment Conference (virtual)
2020	SEP 22	Berenberg and Goldman Sachs Conference (virtual)
2020	SEP 29	Kapitalmarktkonferenz - Family Office Day, Vienna
2020	NOV 11	Quarterly Statement 3 rd Quarter 2020
2020	NOV 16 - 18	Eigenkapitalforum, Germany
2020	NOV 30	Berenberg Conference Pennyhill, London
2020	DEZ 8 - 9	MKK – Münchner Kapitalmarkt Konferenz, Munich





1,631
EMPLOYEES

M€
~197
SALES

M€
~29
EBITDA


M€
~12
OPERATING
CASHFLOW



ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE

INNOVATION SINCE

1908



*All financial indicators relating to
YTD 2020/06 figures*



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst Presentation Q1/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group




ALZCHEM GROUP (IN T€)	31.12.2019	30.06.2020	Deviation	
Intangible assets	1,541	1,360	-181	-11.8%
Tangible assets	165,702	162,969	-2,733	-1.6%
Investment properties				
Right of use (assets)	9,770	8,808	-962	-9.8%
Investments accounted for using the equity				
Financials assets	20	20		
Trade receivables				
Other receivables	470	495	24	5.2%
<i>there of Deferred tax assets for pensions</i>				
Deferred tax assets	34,477	34,950	473	1.4%
SUM NON-CURRENT ASSETS	211,981	208,602	-3,379	-1.6%
Inventories	74,607	73,469	-1,138	-1.5%
Trade receivables	32,501	50,018	17,517	53.9%
Financial assets	0	6	6	>1.000%
Other receivables	14,051	11,702	-2,349	-16.7%
Income tax receivables	381	425	44	11.6%
Cash and cash equivalents	9,061	10,099	1,038	11.5%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	130,602	145,721	15,119	11.6%
SUM ASSETS	342,583	354,323	11,740	3.4%

ALZCHEM GROUP (IN T€)	31.12.2019	30.06.2020	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	69,294	72,750	3,456	5.0%
Other comprehensive income	-48,152	-50,319	-2,167	4.5%
SHARE TO THE SHAREHOLDERS	59,757	61,046	1,289	2.2%
Non-controlling interests	1,592	1,678	85	5.4%
SUM EQUITY	61,350	62,724	1,375	2.2%
Provisions for pensions	134,629	138,153	3,524	2.6%
Other provisions	22,404	23,472	1,068	4.8%
Loans	50,747	44,940	-5,807	-11.4%
Finance lease liabilities	7,710	6,982	-728	-9.4%
Trade liabilities		22	22	
Other liabilities	513	513		
Deferred tax liabilities	4,745	4,466	-279	-5.9%
SUM NON-CURRENT LIABILITIES	220,748	218,547	-2,201	-1.0%
Other provisions	1,732	1,571	-162	-9.3%
Loans	11,935	25,473	13,539	113.4%
Finance lease liabilities	1,706	1,568	-138	-8.1%
Finance liabilities		0	0	
Trade liabilities	24,069	23,871	-198	-0.8%
Other liabilities	19,172	19,094	-78	-0.4%
Income tax liabilities	1,870	1,474	-396	-21.2%
SUM CURRENT LIABILITIES	60,485	73,052	12,566	20.8%
Sum EQUITY AND LIABILITIES	342,583	354,323	11,740	3.4%

PENSION ACCOUNTING (IFRS)

AlzChem Group (M€)



COMMENTS

- Adjustment of market interest rate from 0.90% → 0.80% increased provision
- Continued low cash payments

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Deviation (Q2)	Jun. 19	Jun. 20	Dev. YOY
Revenue	92,123	96,120	99,431	88,398	94,740	102,511			6,391 7%	188,244	197,251	9,008 10%
Changes in inventories of finished goods and work in prc	7,895	-321	-11,883	-553	2,152	-3,162			-2,841 885%	7,574	-1,010	-8,584 1552%
Other income	4,427	6,114	3,670	2,936	2,425	2,648			-3,466 -57%	10,541	5,073	-5,468 -186%
Raw materials and consumables used	-39,541	-38,320	-33,416	-31,112	-35,491	-35,253			3,068 -8%	-77,862	-70,744	7,118 -23%
Employee benefits expense	-30,666	-31,497	-29,313	-30,614	-32,509	-31,733			-237 1%	-62,163	-64,242	-2,080 7%
Other expense	-21,007	-17,473	-14,925	-20,395	-19,002	-18,190			-718 4%	-38,480	-37,192	1,288 -6%
EBITDA	13,231	14,623	13,564	8,659	12,315	16,822			2,199 15%	27,854	29,137	1,283 15%
Depreciation expense	-4,297	-4,302	-4,964	-5,930	-5,582	-5,742			-1,440 33%	-8,599	-11,324	-2,725 46%
Impairment												
EBIT	8,934	10,321	8,601	2,730	6,734	11,080			759 7%	19,255	17,813	-1,442 -53%
Investment income	8	54	26	14	5	20			-34 -63%	62	25	-37 -267%
Other interest and similar income	37	55	24	84	620	-453			-508 -919%	92	167	75 90%
Other interest and similar expense	-1,214	-1,537	-2,359	-287	-874	-925			611 -40%	-2,750	-1,799	951 -331%
Financial result	-1,169	-1,428	-2,309	-190	-248	-1,358			69 -5%	-2,596	-1,606	990 -522%
Result from associates												
Result from ordinary business	7,766	8,893	6,292	2,540	6,485	9,721			828 9%	16,659	16,207	-452 -18%
Taxes on income and profit	-2,212	-2,510	-1,242	-1,381	-2,063	-2,970			-459 18%	-4,723	-5,033	-310 22%
<i>thereof income tax</i>	-2,034	-2,653	-1,651	-1,592	-1,630	-3,300			-647 24%	-4,687	-4,930	-243 15%
<i>thereof change from deferred taxes</i>	-179	143	409	211	-433	330			188 131%	-36	-102	-67 -31%
Annual result	5,553	6,383	5,050	1,159	4,422	6,752			369 6%	11,936	11,174	-762 -66%
<i>thereof minority interests</i>	43	43	43	43	43	43				85	85	
<i>thereof shares held by shareholders</i>	5,510	6,340	5,008	1,116	4,380	6,709			369 6%	11,850	11,088	-762 -68%
Result per share in EUR	0.54 €	0.62 €	0.49 €	0.11 €	0.43 €	0.66 €	- €	- €		1.16 €	1.09 €	

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q2 2019	Q2 2020	Deviation (QoQ)		YTD Jun.2019	YTD Jun.2020	Deviation (YoY)	
Revenue	96,120	102,511	6,391	6.6%	188,244	197,251	9,008	4.8%
Changes in inventories of finished goods and work in progress	-321	-3,162	-2,841	885.4%	7,574	-1,010	-8,584	-113.3%
Other income	6,114	2,648	-3,466	-56.7%	10,541	5,073	-5,468	-51.9%
Raw materials and consumables used	-38,320	-35,253	3,068	-8.0%	-77,862	-70,744	7,118	-9.1%
Employee benefits expense	-31,497	-31,733	-237	0.8%	-62,163	-64,242	-2,080	3.3%
Other expense	-17,473	-18,190	-718	4.1%	-38,480	-37,192	1,288	-3.3%
EBITDA	14,623	16,822	2,199	15.0%	27,854	29,137	1,283	4.6%
Depreciation expense	-4,302	-5,742	-1,440	33.5%	-8,599	-11,324	-2,725	31.7%
Impairment	0	0	0		0	0	0	
EBIT	10,321	11,080	759	7.4%	19,255	17,813	-1,442	-7.5%
Investment income	54	20	-34	-63.3%	62	25	-37	-59.2%
Other interest and similar income	55	-453	-508	-919.1%	92	167	75	81.3%
Other interest and similar expense	-1,537	-925	611	-39.8%	-2,750	-1,799	951	-34.6%
Financial result	-1,428	-1,358	69	-4.9%	-2,596	-1,606	990	-38.1%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	8,893	9,721	828	9.3%	16,659	16,207	-452	-2.7%
Taxes on income and profit	-2,510	-2,970	-459	18.3%	-4,723	-5,033	-310	6.6%
<i>thereof income tax</i>	-2,653	-3,300	-647	24.4%	-4,687	-4,930	-243	5.2%
<i>thereof change from deferred taxes</i>	143	330	188	131.2%	-36	-102	-67	185.2%
Annual result	6,383	6,752	369	5.8%	11,936	11,174	-762	-6.4%
<i>thereof minority interests</i>	43	43	0	0.0%	85	85	0	0.0%
<i>thereof shares held by shareholders</i>	6,340	6,709	369	5.8%	11,850	11,088	-762	-6.4%
Result per share in EUR	0.63 €	0.66 €	0	5.8%	1.17 €	1.10 €	0	-6.4%

CASH FLOW

AlzChem Group



CASHFLOW (IN M€)

	Q2 2019	Q2 2020	1 - 6 2019	1 - 6 2020
Consolidated earnings before taxes	8,893	9,721	16,659	16,207
Depreciation on fixed and intangible assets	4,302	5,742	8,599	11,324
Decrease in pension provisions	-215	-257	-544	-635
Loss (+) / Profit (-) from the sale of non-current assets	-15	-1	-12	-2
Other non-cash income (-) and expenses (+)	3,549	318	5,817	1,473
Financial result	1,428	1,358	2,596	1,606
Interests & Taxes	-2,305	-4,425	-2,508	-6,264
Increase (+) / Decrease (-) Net Working Capital	-10,931	-9,222	-27,951	-11,998
Cashflow from ongoing operations (Net cash flow)	4,705	3,234	2,655	11,711
Cash outflows for investments in fixed assets	-10,301	-4,813	-22,591	-9,623
Cash inflows from the sale of fixed assets	20	1	49	2
Cash inflow from the acquisition / Reverse acquisition				
Cashflow from investing activity	-10,280	-4,812	-22,542	-9,622
Free cashflow	-5,575	-1,578	-19,887	2,090
Deposits (+) / Repayment (-) bank loans long-term			30,102	
Repayment of bank loans long-term	-1,400	-3,951	-1,802	-5,967
Deposits (+) / Repayment (-) from short-term financing lines	13,030	13,654	2,764	13,654
Dividend payments	-9,159	-7,632	-9,159	-7,632
Payment of reduction in leasing liabilities	-361	-462	-727	-932
Payment of transaction costs of capital increases				
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	2,110	1,608	21,007	-1,049
Net increase / decrease in cash and cash equivalents	-3,465	31	1,120	1,041

SEGMENT OVERVIEW BY QUARTER

AlzChem Group



SALES	2018				2019				2020				Deviation PY (Q2)		YTD Q2 2020		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€						
Basics & Intermediates	34,155	36,926	35,896	32,989	35,465	37,844	41,693	34,405	36,012	38,266			423	1%	73,309	74,278	969	1%
Specialty Chemicals	53,917	56,817	49,805	48,876	50,063	51,686	50,952	47,321	52,199	57,854			6,168	11%	101,749	110,053	8,305	8%
Other and Holding	6,450	6,971	6,259	6,145	6,595	6,591	6,786	6,672	6,529	6,391			-200	-3%	13,186	12,920	-266	-2%
<i>Group Consolidation</i>		5					0											
AlzChem Group	94,522	100,719	91,960	88,010	92,124	96,120	99,430	88,398	94,740	102,511			6,391	6%	188,244	197,251	9,007	5%

EBITDA	2018				2019				2020				Deviation PY (Q2)		YTD Q2 2020		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€						
Basics & Intermediates	1,060	188	106	-2,242	1,038	628	3,220	360	1,903	2,485			1,857	75%	1,666	4,388	2,722	163%
Specialty Chemicals	12,648	16,128	9,485	12,431	11,711	12,919	9,218	7,837	10,158	14,457			1,538	11%	24,629	24,615	-15	0%
Other and Holding	759	-262	547	-852	357	838	1,435	1,877	317	81			-757	-938%	1,195	398	-797	-67%
<i>Group Consolidation</i>	589	-152	265	-1,341	125	239	-309	-1,414	-63	-201			-440	219%	364	-264	-628	-173%
AlzChem Group	15,057	15,902	10,402	7,996	13,231	14,623	13,564	8,659	12,315	16,822			2,199	13%	27,854	29,137	1,283	5%

EXECUTIVE TEAM

AlzChem Group AG



KLAUS ENGLMAIER, COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY Production, Engineering, Environment/Safety/Health/Quality, Technology

ANDREAS NIEDERMAIER, CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

DR. GEORG WEICHSELBAUMER, CSO


WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY Marketing, Sales, Innovation management & Process Development, R&D, Product safety and approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Fully Integrated Business Model (“Verbund” System)

Ability to adapt production to satisfy changing end market needs



THE “VERBUND” SYSTEM

- Fully integrated production network
- The output of a production step serves as the basic input for the next production step
- Cost benefits
- Highly specialized production chain as a unique selling point
- Full control over the quality and specification of all products

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Energy efficiency






OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU® S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot® SQ	Silicon nitride powder for the solar industry	Photovoltaics
	Silzot® HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine hydrochloride salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		
	Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Evonik, Aramark, VIACTIV, Degussa Bank)		
	Site services		


KEY SHARE DATA

Share Details as of August 7, 2020



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 19.70
MARKET CAPITALIZATION	EUR 200.5 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



** Information regarding the free float in accordance with section 2.3 of the Guide to the Equity Indices of Deutsche Börse AG, as amended.*